Syros Pharmaceuticals (NASDAQ:SYRS) Upgraded by StockNews.com to “Hold”

StockNews.com upgraded shares of Syros Pharmaceuticals (NASDAQ:SYRSFree Report) from a sell rating to a hold rating in a research note released on Thursday.

Syros Pharmaceuticals Stock Performance

NASDAQ:SYRS opened at $5.35 on Thursday. The stock has a market cap of $112.72 million, a P/E ratio of -1.43 and a beta of 1.79. The stock has a 50 day simple moving average of $6.86 and a 200 day simple moving average of $5.06. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 1.09. Syros Pharmaceuticals has a 1-year low of $2.09 and a 1-year high of $8.17.

Hedge Funds Weigh In On Syros Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP boosted its stake in Syros Pharmaceuticals by 30.0% in the first quarter. Two Sigma Investments LP now owns 13,600 shares of the company’s stock valued at $36,000 after buying an additional 3,139 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Syros Pharmaceuticals by 8.0% in the 4th quarter. Renaissance Technologies LLC now owns 47,235 shares of the company’s stock valued at $170,000 after purchasing an additional 3,500 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Syros Pharmaceuticals by 85.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,550 shares of the company’s stock valued at $61,000 after purchasing an additional 10,400 shares in the last quarter. LPL Financial LLC boosted its stake in shares of Syros Pharmaceuticals by 13.1% in the 2nd quarter. LPL Financial LLC now owns 94,075 shares of the company’s stock valued at $296,000 after purchasing an additional 10,886 shares in the last quarter. Finally, Shay Capital LLC boosted its stake in shares of Syros Pharmaceuticals by 87.3% in the 2nd quarter. Shay Capital LLC now owns 26,426 shares of the company’s stock valued at $83,000 after purchasing an additional 12,317 shares in the last quarter. 91.47% of the stock is owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

(Get Free Report)

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

Featured Stories

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.